SLNO$39.07
$41.5
Chart
Performance
Key Stats
AI SLNO Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldA company with significant thematic potential in rare disease therapeutics but facing fundamental and technical challenges. Suitable for risk-tolerant investors with a long-term horizon.
Thematic
Focused on rare disease therapeutics, Soleno Therapeutics presents a promising niche opportunity with its lead candidate in late-stage clinical trials for Prader-Willi Syndrome.
Fundamental
Persistent net losses, negative earnings per share, and high operating expenses impact valuation and financial health, despite a strong balance sheet and adequate cash reserves.
Technical
The stock is in a general uptrend supported by moving averages, but oscillators indicate overbought conditions and mixed momentum suggesting possible short-term volatility.
| Factor | Score |
|---|---|
| Rare Disease Therapeutics | 75 |
| Clinical Pipeline Progress | 75 |
| Market Focus | 65 |
| Company History & Stability | 60 |
| Employee Base | 60 |
| Factor | Score |
|---|---|
| Valuation | 35 |
| Profitability | 30 |
| Growth | 65 |
| Balance Sheet Health | 85 |
| Cash Flow | 25 |
| Factor | Score |
|---|---|
| Trend Analysis | 75 |
| Momentum | 50 |
| Volume Confirmation | 60 |
| Support & Resistance | 50 |
AI Investing Checklist
Powered by LiveAIBullish Points (5)
Strong Recent Performance
The stock has demonstrated exceptional returns with a 6-month performance of 82.42% and a year-to-date (YTD) gain of 87.09%, reflecting strong investor confidence and momentum.
Healthy Cash Position
Despite negative free cash flow, the company maintains a solid cash position of $87.9 million as of 2024 Q4, providing sufficient liquidity to fund ongoing operations and initiatives.
Bearish Points (6)
Ongoing Losses and Negative EPS
The company reports negative trailing twelve months (TTM) EPS of -4.74, with recent quarters showing continued losses exceeding estimates and large negative surprises, indicating ongoing profitability challenges.
Negative and Volatile PE Ratios
PE ratios are negative and volatile, with TTM PE at -25.6 and quarterly PE ratios reaching as low as -210.8, reflecting losses and uncertainty in earnings expectations.
Calendar
October 2017
6
Next Dividend Date
August 2025
5
Next Earnings Date
H: $
A: $
L: $
H: 32.30M
A: 25.14M
L: 1.69M
Profile
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Seasonals
Price Target
114.56 USD
The 39 analysts offering 1 year price forecasts for SLNO have a max estimate of 145.00 and a min estimate of 97.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Direct competitor developing ACP-101 (Carbetocin) in Phase 3 for hyperphagia in Prader-Willi Syndrome, directly addressing SLNO's primary therapeutic area. [17]
Weight: 90
Major pharmaceutical company with existing growth hormone therapies (e.g., Genotropin) used in Prader-Willi Syndrome, and actively investing in PWS treatment advancements. [12]
Weight: 88
Explicitly mentioned as a top competitor to Soleno, specializing in the development of treatments for rare and ultra-rare genetic diseases. [3]
Weight: 87
Listed as a top competitor to Soleno, a leader in RNAi therapeutics for rare genetic diseases, indicating a similar strategic focus on orphan drug development. [3]